What is SPRY's dilution risk score?

SPRY has a latest available DilutionScore record of 42/100, categorized as medium dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for SPRY, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for SPRY?

DilutionWatch tracks 25 SEC filing types for SPRY including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect SPRY shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For SPRY, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for SPRY tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for SPRY. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

SPRY Dilution Risk Score: 42/100 (MEDIUM)

Score Breakdown

📋 Offering Ability

40

💰 Cash Runway

40

📊 Float Risk

55

⚠️ Warrant Exposure

40

🔄 Convertible Debt

40

Dilution Forecast

☀️

Clear

No significant dilution signals

model est. 0%

No significant dilution signals detected for SPRY.

🔔 Track SPRY — Get forecast alerts →

Market Data

Market Cap$900.68M

Shares Outstanding99.45M

Float42.45M

Cash$143.84M

Debt$96.68M

Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

Field	Current Value	Basis
DilutionScore	42/100	DilutionWatch score record
Shares Outstanding	99.45M	Verified float table or market cache
Public Float	42.45M	Verified float table or market cache
Market Cap	$900.68M	Market data cache
Cash Runway	16.5 months	DilutionWatch score inputs
Shelf Capacity	None in current score inputs	SEC-derived dilution fields
ATM Capacity	None in current score inputs	SEC-derived dilution fields
Outstanding Warrants	None in current score inputs	SEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 2.

Recent SEC source mix: XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 6.8% shares (2026Q1 vs prior)

204 institutional holders · 99.21M shares

#1 RA CAPITAL MANAGEMENT, L.P. 10.86M shares

#2 ORBIMED ADVISORS LLC 8.29M shares

#3 Rubric Capital Management LP 8.00M shares

+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest23.21M

Days to Cover14.1

% of Float54.7%

FINRA data as of Aug 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL WARRANT 2023-12-31

xbrl XBRL CONVERTIBLE 2022-12-31

Full SEC filing analysis available with free account →

Recent News

No recent news

Factual SPRY Dilution Snapshot

ARS Pharmaceuticals, Inc. (SPRY) has a DilutionScore of 42/100, rated Medium dilution risk. Score date: September 12, 2026.

Recent SEC activity tracked for SPRY: xbrl on 2023-12-31; xbrl on 2022-12-31.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.